以1 mmol·L-1油酸孵育HepG2细胞24 h,建立体外高脂模型,在细胞存活率实验（MTT法）的基础上,以脂质清除率为指标,评价茶黄素（TFs）、儿茶素（Cs）和绞股蓝皂苷（SPs）的体外降脂效果;并结合Box-Behnken响应曲面法（RSM）对3种物质体外联合降脂的浓度进行优化。结果表明：茶黄素、儿茶素和绞股蓝皂苷均能清除肝细胞内堆积的脂肪,若三者同时作用,协同效果明显,能起到防治高血脂症的作用。
The antihyperlipdemic activity in vitro of theaflavins(TFs), catechins(Cs) and saponius(SPs) were assessed in lipid clearance rate in the model of HepG2 steatosis by using the admini stration with 1 mmol·L-1 oleic acid(OA) in 24 h. Based on the cell viability test(MTT value), lipid clearance was used to evaluate the effect of TFs, Cs and SPs on HepG2 steatosis. The response surface methodology based on a Box-Behnken experimental design was used to optimize the density of the three extractions for combined lipid-lowering in vitro. Results indicated that TFs, Cs and SPs showed a significant inhibitory effect on TG accumulation in HepG2 cells. The ability of lipid-lowering was significant promoted when the three extractions acted on HepG2 at the same time. TFs, Cs and SPs could showed the prevention and curing effect of hyperlipidemia.
[1] 松井阳吉, 岩田多子. 关于乌龙茶的生理机能[J]. 福建茶叶, 1997(3): 7-11.
[2] 赵丽萍, 邵宛芳. 普洱茶对高脂血症大鼠的降脂和预防脂肪肝作用[J]. 西南农业学报, 2010(2): 579-583.
[3] 吴文华. 晒青毛茶和普洱茶降血脂作用比较试验[J]. 中国茶叶, 2005, 27(1): 15.
[4] Yeh CW, Chen WJ, Chiang CT, et al. Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects[J]. Pharmacogenomics Journal, 2003, 3(5): 267-276.
[5] 徐湘婷, 王鹏, 罗绍忠, 等. 普洱茶调节SD大鼠血脂及保护血管内皮的研究[J]. 茶叶科学, 2010, 30(6): 470-474.
[6] 邓慧君, 曹进. 茶及茶多酚类化合物对血脂水平的影响[J]. 国外医学: 医学地理分册, 2004, 25(3): 101-139.
[7] 敬明武, 葛宇杰, 刘科亮. 茶色素胶囊对大鼠辅助调节血脂的研究[J]. 中国现代医生, 2007, 45(5): 18-19.
[8] 徐甜. 四川边茶茶褐素优化提取及降血脂活性研究[D]. 成都: 四川农业大学, 2010: 3-4.
[9] 陈婷, 彭春秀, 龚加顺, 等. 普洱茶茶褐素对高脂血症大鼠血脂代谢的影响[J]. 中国食品学报, 2011, 11(1): 20-27.
[10] 吴宗群, 王艳. 绞股蓝的化学成份和药理作用研究现状[J]. 中华全科医学, 2011, 9(1): 116-117.
[11] 杨静. 绞股蓝化学成分研究[J]. 陕西中医, 2000, 21(8): 377.
[12] 马平勃, 朱全红, 黄中伟. 绞股蓝泡服对实验性高脂血症及血液流变学的影响[J]. 中国现代应用药学杂志, 2005, 22(6): 454-455.
[13] EGCG和红茶多酚对HepG2细胞脂质代谢相关基因表达的影响[J]. 营养学报, 2006, 28(6): 498-501.
[14] 耿艳艳. 茶多酚复合制剂安全毒理学评价及降血糖作用的研究[D]. 杭州: 浙江大学, 2009: 43-44.
[15] Nehra V, Angulo P, Buchman A, et al. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis[J]. Dig Dis Sci, 2001, 46: 2347-2352.
[16] Fujimoto Y, Onoduka J, Homma K J, et al. Long-chain fattyacids induce lipid droplet formation in a cultured human hepatocyte in amanner dependent of Acyl-CoA synthetase[J]. Biol Pharm Bull, 2006, 29(10): 2174-2180.
[17] 中华全国供销合作总社杭州茶叶研究院. GB/T 21727—2008固态速溶茶儿茶素类含量的检测方法[S]. 北京: 中华人民共和国国家质量监督检验检疫总局, 2008: 1-3.
[18] 中华人民共和国卫生部. 保健食品检验与评价技术规范[S]. 北京: 中华人民共和国卫生部, 2003: 306-307.
[19] 林玲. 调血脂药物体外筛选模型的建立及应用[D]. 福州: 福建中医药大学, 2011: 16-17.
[20] Gómez-Lechón M J, Donato M T, Martínez-Romero A. A human hepatocellular in vitro model to investigate steatosis[J]. Chemico-Biological Interactions, 2007, 165(2): 106-116.
[21] Wang S R, Pessah M, Infante J, et al. Lipid and lipoprotein metabolism in HepG2 cells[J]. Biochimica Biophysica Acta, 1988, 961(3): 351-363.
[22] Vinciguerr M, Carrozzino F, Peyrou M, et al. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN[J]. J Hepatol, 2009, 50(6): 1132-1141.
浙公网安备 33019902000101号 
